Aardvark Therapeutics, Inc. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Expense Ratios
Working Capital Analysis
Valuation Multiples
52-Week Range
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)
$-3
Book Value Per Share
$5
Free Cash Flow Per Share
$-3
Cash Per Share
$2
Revenue Per Share
$0
OCF Per Share
$-3
Return on Equity
-221.5%
Return on Assets
-59.2%
Return on Invested Capital
-190.6%
Current Ratio
10.61
Quick Ratio
10.61
Asset Turnover
0.00
R&D / Revenue
719.3%
SBC / Revenue
18.2%
Capex / Revenue
4.5%
Working Capital
$101M
Net Current Asset Value
$101M
Invested Capital
$107M
OCF / Net Income
0.94
FCF / Net Income
0.94
Accruals Ratio (Sloan)
-2.9%
Net Debt
$-110M
Net Debt / EBITDA
1.76
Capex Coverage
-570.23
Tangible Common Equity
$107M
TCE / Total Assets
91.0%
NOPAT
$-50M
Cash ROIC
-208.8%
WC / Revenue
2867.0%
Capex / D&A
2.64
Reinvestment Rate
-0.1%
Asset Growth vs Revenue Growth
151.2%
Stock Price (FY-end)
$13
Market Cap
$258M
P/B Ratio
2.42
P/TB Ratio
2.42
Enterprise Value
$148M
FCF Yield
-21.1%
Shareholder Yield
-1.5%
R&D Yield
19.0%
Capex Yield
0.0%
Shares Variation (YoY)
391.1%
Beta (5Y)
1.40
Cost of Equity
11.5%
52W High
$17
52W Low
$7
F-Score (Piotroski)
1.00
Z-Score (Altman)
12.54
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.